{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T01:19:32Z","timestamp":1787534372209,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,23]]},"DOI":"10.7759\/cureus.115042","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T01:08:51Z","timestamp":1787533731000},"source":"Crossref","is-referenced-by-count":0,"title":["Sequential Autologous Stem Cell Transplantation and Ciltacabtagene Autoleucel for Concurrent Multiple Myeloma and Presumptive Immunoglobulin Heavy- and Light-Chain Amyloidosis in a Patient With Systemic Lupus Erythematosus"],"prefix":"10.7759","author":[{"given":"Riddhi","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yash","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshitha","family":"Tallapally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini G","year":"2018","unstructured":"Merlini G, Dispenzieri A, Sanchorawala V, Sch\u00f6nland SO, Palladini G, Hawkins PN, Gertz MA. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018, 4:38. 10.1038\/s41572-018-0034-3","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159\/000506696","article-title":"The pathology of amyloidosis in classification: a review","volume":"143","author":"Picken MM","year":"2020","unstructured":"Picken MM. The pathology of amyloidosis in classification: a review. Acta Haematol. 2020, 143:322-34. 10.1159\/000506696","journal-title":"Acta Haematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.414","article-title":"The diagnosis and characteristics of renal heavy-chain and heavy\/light-chain amyloidosis and their comparison with renal light-chain amyloidosis","volume":"83","author":"Nasr SH","year":"2013","unstructured":"Nasr SH, Said SM, Valeri AM, et al.. The diagnosis and characteristics of renal heavy-chain and heavy\/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int. 2013, 83:463-70. 10.1038\/ki.2012.414","journal-title":"Kidney Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders HJ","year":"2020","unstructured":"Anders HJ, Saxena R, Zhao MH, et al.. Lupus nephritis. Nat Rev Dis Primers. 2020, 6:7. 10.1038\/s41572-019-0141-9","journal-title":"Nat Rev Dis Primers"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-629790","article-title":"What is new in diagnosis and management of light chain amyloidosis?","volume":"128","author":"Palladini G","year":"2016","unstructured":"Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis?. Blood. 2016, 128:159-68. 10.1182\/blood-2016-01-629790","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin T","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, et al.. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023, 41:1265-74. 10.1200\/JCO.22.00842","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE- 1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja JG","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, et al.. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE- 1): a phase 1b\/2 open-label study. Lancet. 2021, 398:314-24. 10.1016\/S0140-6736(21)00933-8","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-025-04226-9","article-title":"An atypical cause of amyloidosis: a case of combined heavy and light chain amyloidosis","volume":"26","author":"Gonzalez-Hernandez DR","year":"2025","unstructured":"Gonzalez-Hernandez DR, Hanouneh M, Cervantes CE. An atypical cause of amyloidosis: a case of combined heavy and light chain amyloidosis. BMC Nephrol. 2025, 26:332. 10.1186\/s12882-025-04226-9","journal-title":"BMC Nephrol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis","volume":"79","author":"Gertz MA","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH, et al.. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol. 2005, 79:319-28. 10.1002\/ajh.20381","journal-title":"Am J Hematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini G","year":"2014","unstructured":"Palladini G, Hegenbart U, Milani P, et al.. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014, 124:2325-32. 10.1182\/blood-2014-04-570010","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.12.018","article-title":"First 23-patient safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R\/R light chain (AL) amyloidosis, NXC-201","volume":"32","author":"Landau HJ","year":"2026","unstructured":"Landau HJ, Raza S, Rosenberg A, et al.. First 23-patient safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R\/R light chain (AL) amyloidosis, NXC-201. Transplant Cell Ther. 2026, 32:S4. 10.1016\/j.jtct.2025.12.018","journal-title":"Transplant Cell Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2020.08.004","article-title":"Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignancies","volume":"12","author":"Jaggers JL","year":"2021","unstructured":"Jaggers JL, Giri S, Klepin HD, et al.. Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignancies. J Geriatr Oncol. 2021, 12:235-8. 10.1016\/j.jgo.2020.08.004","journal-title":"J Geriatr Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04425-z","article-title":"CAR T cell therapy efficacy and safety in SLE: a systematic review and pooled analysis of 47 patients across 10 studies","volume":"399","author":"Sayed OA","year":"2026","unstructured":"Sayed OA, Ellebedy M, Abu-Alsaud MA, Meligy AI, Gheita TA. CAR T cell therapy efficacy and safety in SLE: a systematic review and pooled analysis of 47 patients across 10 studies. Naunyn Schmiedebergs Arch Pharmacol. 2026, 399:1565-88. 10.1007\/s00210-025-04425-z","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain T","year":"2020","unstructured":"Jain T, Knezevic A, Pennisi M, et al.. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020, 4:3776-87. 10.1182\/bloodadvances.2020002509","journal-title":"Blood Adv"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.287783","article-title":"Cytopenias and infections following ciltacabtagene autoleucel in heavily pretreated relapsed or refractory multiple myeloma","volume":"111","author":"Dima D","year":"2026","unstructured":"Dima D, Logue JM, Waqar SH, et al.. Cytopenias and infections following ciltacabtagene autoleucel in heavily pretreated relapsed or refractory multiple myeloma. Haematologica. 2026, 111:184-95. 10.3324\/haematol.2025.287783","journal-title":"Haematologica"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn K","year":"2022","unstructured":"Wudhikarn K, Perales MA. Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy. Bone Marrow Transplant. 2022, 57:1477-88. 10.1038\/s41409-022-01756-w","journal-title":"Bone Marrow Transplant"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-310704","article-title":"Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response","volume":"103","author":"Grogan M","year":"2017","unstructured":"Grogan M, Dispenzieri A, Gertz MA. Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response. Heart. 2017, 103:1065-72. 10.1136\/heartjnl-2016-310704","journal-title":"Heart"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini G","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA, et al.. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012, 30:4541-9. 10.1200\/JCO.2011.37.7614","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/518488-sequential-autologous-stem-cell-transplantation-and-ciltacabtagene-autoleucel-for-concurrent-multiple-myeloma-and-presumptive-immunoglobulin-heavy--and-light-chain-amyloidosis-in-a-patient-with-systemic-lupus-erythematosus","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T01:08:52Z","timestamp":1787533732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/518488-sequential-autologous-stem-cell-transplantation-and-ciltacabtagene-autoleucel-for-concurrent-multiple-myeloma-and-presumptive-immunoglobulin-heavy--and-light-chain-amyloidosis-in-a-patient-with-systemic-lupus-erythematosus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,23]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.115042","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,23]]}}}